Alnylam presents new data for zilebesiran, an investigational rnai therapeutic for the treatment of hypertension, at the american heart association scientific sessions 2021

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced positive interim results from the ongoing phase 1 study of zilebesiran (formerly known as aln-agt), an investigational subcutaneous rnai therapeutic targeting liver-expressed angiotensinogen (agt) in development for the treatment of hypertension. findings on the pharmacodynamic and antihypertensive effects of zilebesiran six months after a single dose were pres
ALNY Ratings Summary
ALNY Quant Ranking